期刊文献+

过敏性紫癜患儿基质金属蛋白酶-9水平的变化及临床意义 被引量:2

下载PDF
导出
摘要 目的通过检测过敏性紫癜(HSP)和紫癜性肾炎(HSPN)患儿血清和尿液中基质金属蛋白酶-9(MMP-9)水平及部分自身抗体指标,探索它们与HSP病变程度的关系。方法收集20例HSP(HSP组)、15例HSPN患儿(HSPN组)以及20例健康儿童(对照组)的血清和尿液,ELISA检测血清和尿液中MMP-9水平,间接免疫荧光法检测血清抗核抗体(ANA)和抗中性粒细胞胞浆抗体(ANCA),免疫斑点法检测抗可提取性核抗原抗体谱。结果 (1)HSPN组血清MMP-9为(469.82±38.34)ng/mL,显著高于HSP组的(244.71±88.23)ng/mL和对照组的(50.81±24.91)ng/mL,HSPN组尿液MMP-9为(76.46±24.25)ng/mL也显著高于HSP组的(27.03±8.85)ng/mL和对照组的(6.32±3.20)ng/mL,差异均有统计学意义(均P<0.01)。(2)35例患儿,ANA阳性1例,ANCA阳性1例(pANCA阳性),抗可提取性核抗原抗体谱(nRNP、Sm、JO-1、SS-A、SS-B、scl-70)均为阴性。结论 HSPN患儿血清及尿液中MMP-9水平均显著高于HSP患儿和健康儿童,提示MMP-9不仅参与HSPN的发生发展过程,且可能与肾损害有关。HSP患者ANA、ANCA等自身抗体检测的临床意义有待进一步评估。
出处 《广东医学》 CAS CSCD 北大核心 2011年第22期2945-2946,共2页 Guangdong Medical Journal
基金 广东省医学科研基金立项项目(编号:A2009239)
  • 相关文献

参考文献8

  • 1RAFFETFO J D, KHALIL R A. Matrix metalloproteinases and their inhibitors in vascular remodeling and vascular disease [ J ]. Biochem Pharmacol, 2008, 75 (2) : 346-359.
  • 2胡亚美,诸福堂.实用儿科学[M].7版.北京:人民卫生出版社,2002:1174
  • 3中华医学会儿科学分会肾脏病学组,姚勇,杨霁云,陈述枚,丁洁.小儿肾小球疾病的临床分类、诊断及治疗[J].中华儿科杂志,2001,39(12):746-749. 被引量:1533
  • 4魏珉.继发性肾小球疾病诊疗进展[J].实用儿科临床杂志,2004,19(1):1-4. 被引量:11
  • 5MAHAJAN N, DHAWAN V, MALIK S, et al. Implication of' oxidative stress and its correlation with activity of matrix metalloproteinases in patients with Takayasu's arteritis disease[J]. Int J Cardiol, 2010, 145(2) : 286 -288.
  • 6王晓慧,黄睿,李守新.基质金属蛋白酶-9在系统性红斑狼疮发病中的作用[J].临床内科杂志,2005,22(12):855-856. 被引量:6
  • 7RASHTAK S, PITFELKOW M R. Skin involvement in systemic autoimmune diseases[ J]. Curr Dir Autoimmun, 2008, 10 : 344-358.
  • 8ROBSON W L, LEUNG A K, WOODMAN R C. The absence of anti-neutrophil cytoplasmic antibodies in patients with Henoch-Schonlein purpura [ J ]. Pediatr Nephrol, 1994, 8 ( 3 ) : 295-298.

二级参考文献16

  • 1Visse R, Nagase H. Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases: Structure, Function, and Biochemistry. Circulation Research ,2003,92:827-839.
  • 2Giannelli G, Erriquez R, Iannone F, et al. MMP-2, MMP-9, TIMP-1 and TIMP-2 levels in patients with rheumatoid arthritis and psoriatic arthritis. Clin Exp Rheumato1,2004 ,22 :335-338.
  • 3Hulkkonen J, Pertovanra M, Antonen J, et al. Matrix metalloproteinase 9 (MMP-9) gene polymorphism and MMP-9 plasma levels in primary Sj? gren's syndrome. Rheumatology, 2004,43 : 1476 - 1479.
  • 4Mawrin C, Brunn A, Rocken C, et al. Peripheral neuropathy in systemic lupus erythematosus:pathomorphological features and distribution pattern of matrix metalloproteinases. Acta Neuropathol (Berl) ,2003,105 :365 -372.
  • 5Vaday GG, Hershkoviz R, Rahat MA, et al. Fibronectin-bound TNF-alpha stimulates monocyte matrix metalloproteinase-9 expression and regulates chemotaxis. J Leukoc Biol,2000,68: 737-747.
  • 6Opdenakker G, Van den Steen PE. Gelatinase B : a tuner and amplifier of immune functions. Trends in Immunology,2001,22 : 571-579.
  • 7Huhtala P,Tuuttila A, Chow LT, et al. Complete structure of the human gene for 92-kDa type IV collagenase. J. Biol. Chem, 1991,266 : 16485-16490.
  • 8Faber-Elmann A, Eilat E, Zinger H, et al. A peptide based on an anti-DNA autoantibody downregulates matrix metalloproteinases in murine models of lupus. Clin Immunol,2002,105:223-232.
  • 9Urushihara M, Kagami S, Kuhara T, et al. Glomerular distribution and gelatinolytic activity of matrix metalloproteinases in human glomerulonephritis. Nephrol Dial Transplant,2002,17:1189-1196.
  • 10Faber-Elmann A ,Sthoeger Z,Tchemiack A,et al. Activity of matrix metalloproteinase-9 is elevated in sera of patients with systemic lupus erythematosus. Clin Exp Immunol,2002,127:393-398.

共引文献2220

同被引文献20

引证文献2

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部